materIals and methods

Patients
Patients with migraine were recruited at the Department of Neurology, the Sixth People's Hospital of Fuyang City between March 2018 and July 2018. The migraine patients were diagnosed by two neurologists, according to the 2013 Headache Classification Committee of International Headache Society migraine diagnosis standard. All patients in the migraine group had not received any prophylactic migraine medication in the previous week and had not taken antibiotics within the previous 3 months. The healthy persons who had no personal or family history of migraine were recruited as controls. All participants underwent a detailed neurological examination and tests of head computed tomography angiography, head magnetic resonance imaging, electrocardiogram, white blood cell count, C-reactive protein (CRP), blood sugar, and lipids. Patients who had nonmigraine headache, inflammatory or autoimmune diseases, abnormal CRP levels, hypertension, diabetes mellitus, obesity, metabolic syndrome, or ischemic cerebrovascular disease were excluded from this study. The study was approved by the Ethical Committee of the Sixth People's Hospital of Fuyang City. Written informed consent was obtained from each participant.
Samples
Blood samples were obtained within 2 h from the onset of migraine headache from the jugular venous. [17] Blood samples were also obtained from healthy individuals. Inflammatory factor concentration in the serum was analyzed. Two 10 ml blood samples were drawn into glass tubes containing 35 μmol of dipotassium-EDTA and 1500 kallikrein inactivator units of trasylol. The tubes were kept in an ice bath and then centrifuged at 2000×g for 15 min at 4°C. The plasma was separated from the cells, stored at −80°, and analyzed through commercially available enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay
The protein levels of IL-1 β, IL-2, IL-6, IL-10, TNF-α, and CGRP were determined from the sera of patients with migraine and control subjects. Commercial ELISA kits were used in accordance with the manufacturers' instructions. The assays were performed in duplicate in 96-well plates, and the results were presented as picograms per milliliter. The collected samples from each of the two groups were analyzed on the same day on one ELISA plate for each protein. The following kits were used: human IL-1β ELISA kit (ab100562; Abcam, Cambridge, MA, USA; detection threshold of 1.5 pg/ml; intra-and inter-assay coefficient of variation of <11%); human IL-2 ELISA kit (ab174444; Abcam, Cambridge, MA, USA; detection threshold of 9 pg/ml; intra-and inter-assay coefficient of variation of <6%); human IL-6 ELISA kit (ab46027; Abcam, Cambridge, MA, USA; detection threshold of 2 pg/ml; intra-and inter-assay coefficient of variation of <8.6%); human IL-10 ELISA kit (ab100549; Abcam, Cambridge, MA, USA; detection threshold of 1 pg/ml; intra-and inter-assay coefficient of variation of <10%); human TNF-α ELISA kit (ab46087; Abcam, Cambridge, MA, USA; detection threshold of 15 pg/ml; intra-and inter-assay coefficient of variation of <10.3%); human CGRP ELISA kit (CEA876Hu; USCN Life Science Inc., Hubei, China; detection threshold of 5.35 pg/ml; intra-and inter-assay coefficient of variation of <12%).
Statistical analysis
The inflammatory factor and CGRP concentration are presented as mean ± SEM Differences between groups were statistically analyzed using the t-test depending on different variables with SAS 8.0 Software (SAS Institute INC, USA). Spearman rank correlation coefficient was also determined to calculate the correlation between CGRP and inflammatory factors levels. P < 0.05 was considered statistically significant.
results
Ultimately, 47 patients with migraine (26 females and 21 males, mean age = 35.2 ± 9.3 years) and 38 healthy volunteers (22 females and 16 males, mean age = 32.4 ± 6.1 years) were included. Among the migraine patients, 20 were without aura (MO) (11 females and 9 males, mean age = 34.1 ± 5.3 years) and 27 were with aura (MA) (15 females and 12 males, mean age = 36.3 ± 10.4 years). There was no significant difference between the migraine and control group or MO and MA groups in age and gender (P > 0.05). There were 16 patients with episodic migraine (EM) (fewer than 15 headache days per month) and 31 patients with chronic migraine (CM) (15 or more headache days per month) [ Table 1 ].
Among all the inflammatory factors and CGRP we detected, the level of IL-1β, IL-6, TNF-α, and CGRP in migraine group were significantly higher than normal group (P < 0.05) [ Table 2 ]. However, the levels of all inflammatory factors and CGRP were similar between MO and MA groups (P > 0.05) [ Table 3 ].
The level of CGRP was significantly correlated with IL-1β (r = 0.30, P < 0.05) and IL-6 (r = 0.94, P < 0.05) [ Figure 1 ], but not correlated with IL-2 (r = −0.047, P = 0.75), IL-10 (r = 0.12, P = 0.43), or TNF-α (r = 0.05, P = 0.72).
dIscussIon
Migraine is a primary headache disorder which seriously affects the daily life of patients. [1, 18] As understanding of the neural pathways has advanced, CGRP-based mechanisms have arisen. CGRP is found in the trigeminovascular nociceptive system widely in the trigeminal ganglion and brain stem. CGRP may be involved in migraine at both a central and peripheral level. Previous studies showed that the stimulation of brainstem could activate the trigeminovascular system and cause releasing of CGRP. [19] [20] [21] Moreover, several studies showed the CGRP level in serum raised during migraine attack and fallen after effective treatment. The significance of CGRP in migraine pathophysiology has been supported by several lines of clinical evidence. [6, 7] In our study, we found that the level of CGRP in migraine group was significantly higher than normal group, but it is similar between MO and MA groups. Similar results have been obtained measuring serum levels of CGRP in migraine patients during attacks. While the role of CGRP in migraine attack was still unclear, but several studies showed the CGRP may cause migraine by inducing secretion of cytokines.
Cytokines play an important role in several physiological courses, such as inflammation and pain. Pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6, and anti-inflammatory cytokines, such as IL-10 have been reported to play a significant role in the modulation of pain threshold and they could contribute to trigeminal nerve fibers sensitization. [22, 23] Previous studies supported that cytokines might be considered in inflammation and hyperalgesia in migraine. [24, 25] Similar to the earlier studies, we found migraine patients had a higher IL-6, IL-1β, and TNF level than healthy controls in our study, but we did not find a significant difference between migraine with aura and migraine without aura. The increasing IL-6, IL-1 β and TNF level support that cytokines may be related with the pathogenesis of migraine. The cause of elevated cytokine levels during attacks is unknown; however, CGRP may play a role in this event. It has been shown that CGRP stimulates the production and release of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6 from human lymphocytes "in vitro" through the link to specific receptors on these cells. [10, 26] In addition, the jugular plasma levels of CGRP are increased in the 1 st h of migraine attacks, may cause neurogenic inflammation and vasodilation in animal models. Recent data have shown that CGRP possibly through stimulation of their selective receptors on T-cells, trigger the secretion of cytokines. [27, 28] Therefore, it is possible that the pain of migraine attack is related to the release of CGRP and its ability to induce a secretion of cytokine from white cells, platelets, and endothelium. In our study, we found the level of CGRP was related significantly with the level of IL-1β (r = 0.30, P < 0.05) and IL-6 (r = 0.94, P < 0.05).
In conclusion, our results suggest that IL-1β and IL-6 may be involved in the pathogenesis of migraine attacks and CGRP related with the secretion of cytokines. Following this hypothesis, possible future drugs that prevent cytokine production or block CGRP release from trigeminal vascular endings may be a useful strategy in the treatment of migraine.
In our study, the IL-6 level was related with CGRP level most significantly. However, the role of IL-6 to induce migraine has not yet been explored. Several studies showed that IL-6 can activate the mitogen-activated protein kinase (MAPK) signaling pathway in trigeminal ganglion neurons. Moreover, the induction and maintenance of various pain conditions were activated by the ERK1/2 MAPK pathway. [29, 30] Recent work showed that the voltage-gated sodium channels, such as Nav1.3 and Nav1.8, can been regulated by MAPK pathway in DRG neurons and the voltage-gated sodium channels play important role in neuralgia. [31, 32] Consequently, we believe the migraine may be caused by cytokines, such as IL-6 and IL-1β which induced by CGRP.
Our study had limitations certainly, such as we just collected the blood from jugular venous because a large number of studies had shown that the level of CGRP in jugular venous but not cubital venous was higher in migraine patients than healthy volunteers. In the present study, we did not compare the CGRP and cytokines between CM and EM patients as well as between in and out of an attack, we will explore these points in the next studies.
conclusIons
In our study, we found migraine patients had a higher IL-6, IL-1β, and TNF level than healthy controls and the level of CGRP was related significantly with the level of IL-1β and IL-6. In conclusion, our results suggest that IL-1β and IL-6 may be involved in the pathogenesis of migraine attacks and CGRP related with the secretion of cytokines.
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